Dyne Therapeutics Inc (DYN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Dyne Therapeutics Inc (DYN) has a cash flow conversion efficiency ratio of -0.168x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-144.92 Million) by net assets ($865.05 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Dyne Therapeutics Inc (DYN) total market value for the company's overall valuation and market capitalisation.
Dyne Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2007–2025)
This chart illustrates how Dyne Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Dyne Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Dyne Therapeutics Inc ranked by their cash flow conversion efficiency. Explore how high is Dyne Therapeutics Inc's earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shijiazhuang Changshan Textile Co Ltd
SHE:000158
|
-0.054x |
|
Qingdao East Steel Tower Stock Co Ltd
SHE:002545
|
0.055x |
|
Shanghai Lingang Holdings Co Ltd A
SHG:600848
|
-0.002x |
|
Steven Madden Ltd
NASDAQ:SHOO
|
0.219x |
|
NovaGold Resources Inc
TO:NG
|
-0.005x |
|
Kemira Oyj
HE:KEMIRA
|
0.075x |
|
Becle S.A.B. de C.V
MX:CUERVO
|
0.026x |
|
California Water Service Group
NYSE:CWT
|
0.035x |
Annual Cash Flow Conversion Efficiency for Dyne Therapeutics Inc (2007–2025)
The table below shows the annual cash flow conversion efficiency of Dyne Therapeutics Inc from 2007 to 2025. View Dyne Therapeutics Inc (DYN) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $972.13 Million | $-403.21 Million | -0.415x | +10.65% |
| 2024-12-31 | $629.84 Million | $-292.37 Million | -0.464x | +77.48% |
| 2023-12-31 | $91.29 Million | $-188.16 Million | -2.061x | -238.53% |
| 2022-12-31 | $252.36 Million | $-153.65 Million | -0.609x | -87.49% |
| 2021-12-31 | $368.20 Million | $-119.56 Million | -0.325x | -139.05% |
| 2020-12-31 | $342.37 Million | $-46.51 Million | -0.136x | +83.89% |
| 2019-12-31 | $14.04 Million | $-11.83 Million | -0.843x | -198.79% |
| 2018-12-31 | $-4.88 Million | $-4.16 Million | 0.853x | +177.34% |
| 2017-12-31 | $1.90 Billion | $585.00 Million | 0.308x | -7.04% |
| 2016-12-31 | $2.04 Billion | $676.00 Million | 0.331x | +928.71% |
| 2015-12-31 | $2.92 Billion | $94.00 Million | 0.032x | +256.91% |
| 2014-12-31 | $3.02 Billion | $-62.00 Million | -0.021x | -125.90% |
| 2013-12-31 | $2.21 Billion | $175.00 Million | 0.079x | +550.46% |
| 2012-12-31 | $2.50 Billion | $-44.00 Million | -0.018x | +2.26% |
| 2011-12-31 | $1.11 Billion | $-20.00 Million | -0.018x | -111.68% |
| 2010-12-31 | $2.75 Billion | $423.00 Million | 0.154x | +239.92% |
| 2009-12-31 | $2.98 Billion | $135.00 Million | 0.045x | -36.29% |
| 2008-12-31 | $4.49 Billion | $319.00 Million | 0.071x | -5.53% |
| 2007-12-31 | $4.53 Billion | $341.00 Million | 0.075x | -- |
About Dyne Therapeutics Inc
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal mus… Read more